

In Opposition:

AARP
Rick Bennett

America's Health Insurance Plans
(AHIP)
Elise Brown

BlueCross BlueShield of Oregon
Tom Holt
John Powell
John C. Powell

Bridgespan Health
Tom Holt
John Powell
John C. Powell

CVS Caremark
Eric Douglas

ExpressScripts
Meredith Shield

Health Net Health Plan of Oregon,
Inc.
Lisa Truszel

Kaiser Permanente
Jeremy Vandehey

Moda Health
Fawn Barrie

Mylan Inc.
Fawn Barrie

National Association of Chain Drug
Stores
Lis Houchen

Oregon Community Pharmacy
Council
Shawn Miller

Oregon Society of Health System
Pharmacists
Bill Cross

Oregon State Pharmacy
Association
Bill Cross

Pharmaceutical Care Management
Association (PCMA)
Greg Peden
Kelsey Wilson

Providence Health and Services
Jessica Adamson

UnitedHealth Group
Jessica Adamson

Please Oppose the -4 Amendment to HB 4110-A4

Currently, The U.S. Food and Drug Administration (FDA) is working to create a process for the approval of biosimilars and determining interchangeability. The FDA is fully cognizant of the complex nature of biologics and has made clear that the standards they develop for determining whether a biosimilar is interchangeable with an approved reference product will be rigorous. There are no biosimilars on the market in the United States at this point and they have not yet received any applications.

During the 2013 session, the proponents and opponents of the biosimilar legislation worked hard to come up with a compromise that we could all agree to. One part of that compromise was that this issue would not be brought up again until the 2015 session (SB 460.)

We feel this amendment is not in the spirit of the compromise that was agreed to last session. We have serious concerns that this will result in increased costs for patients and plan sponsors in the long term and create access barriers for lower cost options. Additionally, under federal law, insulin is not a biologic.

In 2012, nearly 500,000 prescriptions for Oregon patients were for insulin, over 66,000 for Oregon Medicaid patients. Imposing prescriber notification requirements for insulin scripts would impose an unduly burdensome requirement on pharmacies.

We are opposed to this amendment for these reasons and urge your "no" vote.